ALK and lung adenocarcinoma: We present a patient with Anaplastic lymphoma kinase (<i>ALK</i>) fusion lung adenocarcinoma who received sequential treatment with ALK tyrosine kinase inhibitor (TKI) (crizotinib, PFS:32.3 months and then conteltinib, PFS: 29 months).